Becerra, Carlos
Baylor University Medical Center
4 papers on CoChatORCID 0009-0006-7735-8010
Most cited papers
- Verified
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., et al. (2012) · The Lancet Oncology
Melanoma and MAPK PathwaysProtein Tyrosine Phosphatases
Cited by 552
- Verified
Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring
Shi, Y., Gao, W., Lytle, N. K., Huang, P., Yuan, X., Dann, A. M., Ridinger-Saison, M., DelGiorno, K. E., Antal, C. E., Liang, G., et al. (2019) · Nature
Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment
Cited by 431
- Verified
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
Tolcher, A. W., Patnaik, A., Papadopoulos, K. P., Rasco, D. W., Becerra, C. R., Allred, A. J., Orford, K., Aktan, G., Ferron-Brady, G., Ibrahim, N., et al. (2015) · Cancer Chemotherapy and Pharmacology
Melanoma and MAPK PathwaysPI3K/AKT/mTOR signaling in cancer
Cited by 158
- Verified
A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in platinum-resistant ovarian cancer
Garcia, A. A., Hays, J. L., Cote, G. M., Becerra, C., Langleben, A., Lau, S. K., Roman, L. D., McCormick, C. C., Richards, D. A., Braiteh, F. S., et al. (2016) · Journal of Clinical Oncology
Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy
Cited by 7
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free